Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma
Kesang Li(State Key Laboratory of Oncogene and Related Genes), Zonghai Li(Guizhou Normal University)
Cited by 33
Related Papers
Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma
|Molecular Therapy|2017|184
CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer
|Molecular Therapy|2023|80
Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion protein
|Cancer Immunology Immunotherapy|2018|63